Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
As the COVID-19 pandemic transitions into endemicity, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen-based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist adjuvant, BECC 470. K18-hACE2 mice were primed and boosted at four-week intervals with either VLP-RBD-BECC or mRNA-1273. Both VLP-RBD-BECC and mRNA-1273 vaccination resulted in production of RBD-specific IgA antibodies in serum. RBD-specific IgA was also detected in the nasal wash and lung supernatants and were highest in VLP-RBD-BECC vaccinated mice. Interestingly, VLP-RBD-BECC vaccinated mice showed slightly lower levels of pre-challenge IgG responses, decreased RBD-ACE2 binding inhibition, and lower neutralizing activity in vitro than mRNA-1273 vaccinated mice. Both VLP-RBD-BECC and mRNA-1273 vaccinated mice were protected against challenge with a lethal dose of Delta variant SARS-CoV-2. Both vaccines limited viral replication and viral RNA burden in the lungs of mice. CXCL10 is a biomarker of severe SARS-CoV-2 infection and we observed both vaccines limited expression of serum and lung CXCL10. Strikingly, VLP-RBD-BECC when administered intranasally, limited lung inflammation at early timepoints that mRNA-1273 vaccination did not. VLP-RBD-BECC immunization elicited antibodies that do recognize SARS-CoV-2 Omicron variant. However, VLP-RBD-BECC immunized mice were protected from Omicron challenge with low viral burden. Conversely, mRNA-1273 immunized mice had low to no detectable virus in the lungs at day 2. Together, these data suggest that VLP-based vaccines paired with BECC adjuvant can be used to induce protective mucosal and systemic responses against SARS-CoV-2.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Vaccine - 41(2023), 34 vom: 31. Juli, Seite 5003-5017 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lee, Katherine S [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.07.2023 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.vaccine.2023.06.080 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM359085539 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM359085539 | ||
003 | DE-627 | ||
005 | 20240412232439.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.vaccine.2023.06.080 |2 doi | |
028 | 5 | 2 | |a pubmed24n1373.xml |
035 | |a (DE-627)NLM359085539 | ||
035 | |a (NLM)37407405 | ||
035 | |a (PII)S0264-410X(23)00783-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lee, Katherine S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.07.2023 | ||
500 | |a Date Revised 12.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
520 | |a As the COVID-19 pandemic transitions into endemicity, seasonal boosters are a plausible reality across the globe. We hypothesize that intranasal vaccines can provide better protection against asymptomatic infections and more transmissible variants of SARS-CoV-2. To formulate a protective intranasal vaccine, we utilized a VLP-based platform. Hepatitis B surface antigen-based virus like particles (VLP) linked with receptor binding domain (RBD) antigen were paired with the TLR4-based agonist adjuvant, BECC 470. K18-hACE2 mice were primed and boosted at four-week intervals with either VLP-RBD-BECC or mRNA-1273. Both VLP-RBD-BECC and mRNA-1273 vaccination resulted in production of RBD-specific IgA antibodies in serum. RBD-specific IgA was also detected in the nasal wash and lung supernatants and were highest in VLP-RBD-BECC vaccinated mice. Interestingly, VLP-RBD-BECC vaccinated mice showed slightly lower levels of pre-challenge IgG responses, decreased RBD-ACE2 binding inhibition, and lower neutralizing activity in vitro than mRNA-1273 vaccinated mice. Both VLP-RBD-BECC and mRNA-1273 vaccinated mice were protected against challenge with a lethal dose of Delta variant SARS-CoV-2. Both vaccines limited viral replication and viral RNA burden in the lungs of mice. CXCL10 is a biomarker of severe SARS-CoV-2 infection and we observed both vaccines limited expression of serum and lung CXCL10. Strikingly, VLP-RBD-BECC when administered intranasally, limited lung inflammation at early timepoints that mRNA-1273 vaccination did not. VLP-RBD-BECC immunization elicited antibodies that do recognize SARS-CoV-2 Omicron variant. However, VLP-RBD-BECC immunized mice were protected from Omicron challenge with low viral burden. Conversely, mRNA-1273 immunized mice had low to no detectable virus in the lungs at day 2. Together, these data suggest that VLP-based vaccines paired with BECC adjuvant can be used to induce protective mucosal and systemic responses against SARS-CoV-2 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
650 | 4 | |a COVID-19 vaccine | |
650 | 4 | |a Delta variant | |
650 | 4 | |a Intranasal vaccine | |
650 | 4 | |a K18-hACE2 mice | |
650 | 4 | |a Omicron variant | |
650 | 4 | |a SARS-CoV-2 | |
650 | 7 | |a K-18 conjugate |2 NLM | |
650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
650 | 7 | |a EPK39PL4R4 |2 NLM | |
650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
650 | 7 | |a Immunoglobulin A |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
700 | 1 | |a Rader, Nathaniel A |e verfasserin |4 aut | |
700 | 1 | |a Miller-Stump, Olivia A |e verfasserin |4 aut | |
700 | 1 | |a Cooper, Melissa |e verfasserin |4 aut | |
700 | 1 | |a Wong, Ting Y |e verfasserin |4 aut | |
700 | 1 | |a Shahrier Amin, Md |e verfasserin |4 aut | |
700 | 1 | |a Barbier, Mariette |e verfasserin |4 aut | |
700 | 1 | |a Bevere, Justin R |e verfasserin |4 aut | |
700 | 1 | |a Ernst, Robert K |e verfasserin |4 aut | |
700 | 1 | |a Heath Damron, F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 41(2023), 34 vom: 31. Juli, Seite 5003-5017 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2023 |g number:34 |g day:31 |g month:07 |g pages:5003-5017 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2023.06.080 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2023 |e 34 |b 31 |c 07 |h 5003-5017 |